MURRYSVILLE, Pa., May 15, 2015 /PRNewswire/ -- Respironics, Inc., a Philips business, today provided the following response to ResMed’s Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation ...
On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...
SAN DIEGO, May 13, 2015 /PRNewswire/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint.
SAN DIEGO, May 13, 2015 /CNW/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was ...
- Safety Signal of Increased Cardiovascular Mortality Found For ASV Therapy In People With Predominant Central Sleep Apnea and Symptomatic Chronic Heart Failure - Results and Safety Signal Observed ...
Primary results from ResMed Inc.’s RMD CAT-HF trial showcased the significance of adaptive servo-ventilation (ASV) therapy in the treatment of heart failure (HF). Data were presented at the European ...
Medical device company ResMed Inc. RMD recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA). According to ...
On Jun 19, 2015, we issued an updated research report on ResMed, Inc. RMD. Recently, ResMed faced a major blow as its phase III SERVE-HF study of ASV failed to meet its primary endpoint. In fact, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback